::Artisan Pharma:: Art 123 / Advisory Board






Gordon R. Bernard, MD Mark Crowther, MD Charles Esmon, PhD Jawed Fareed, PhD, DSC, FACB Kenneth J. Gorelick, MD, Chairman John F. Hannigan Marcel Levi, MD, PhD Joseph E. Parrillo, MD Jean-Louis Vincent, MD ART 123 Program Advisory Board Artisan has recruited a team of some of the most renowned experts in sepsis, critical care and hematology specifically to help guide the development and commercialization of ART 123. Gordon R. Bernard, MD Dr. Bernard is a subspecialist in pulmonary and critical care medicine whose areas of interest include sepsis and acute respiratory distress syndrome (ARDS). As Director of the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt University School of Medicine, he oversees a multifaceted lung research center and directs his own research programs. His research has primarily focused on improving the care and outcomes of critically ill patients with sepsis and respiratory failure. Because of his expertise and integrity in this specialty, Dr. Bernard has been called upon to serve in an advisory capacity by the National Heart Lung and Blood Institute of the National Institutes of Health. In addition, he was the Primary Investigator for the Phase III PROWESS trial of rh-Activated Protein C for severe sepsis, which led to its becoming the first approved drug for this disease. Dr. Bernard is currently the chairman of the steering committee of the ARDS clinical trials network, a 10-year NIH-sponsored cohort investigation of ARDS in ICU patients. He graduated with a double major (biology and chemistry) from the University of Southwestern Louisiana and earned his medical degree from Louisiana State University, where he was elected to the Alpha Omega Alpha national honor society. Dr. Bernard has written or co-authored more than 150 articles, book chapters and editorials.

Home Profile Management Board of Directors Art 123 Advisory Board Investors/Partners

ART 123 Program Advisory Board

Artisan has recruited a team of some of the most renowned experts in sepsis, critical care and hematology specifically to help guide the development and commercialization of ART 123.